Acer Therapeutics Inc. (ACER): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACER POWR Grades
- ACER scores best on the Growth dimension, with a Growth rank ahead of 91.43% of US stocks.
- ACER's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- ACER ranks lowest in Momentum; there it ranks in the 5th percentile.
ACER Stock Summary
- Acer Therapeutics Inc's market capitalization of $35,346,303 is ahead of only 3.61% of US-listed equities.
- The ratio of debt to operating expenses for Acer Therapeutics Inc is higher than it is for about merely 0.46% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ACER comes in at -43.45% -- higher than that of just 6.13% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Acer Therapeutics Inc, a group of peers worth examining would be DAIO, LCTX, PDEX, EPZM, and CSLT.
- ACER's SEC filings can be seen here. And to visit Acer Therapeutics Inc's official web site, go to www.acertx.com.
ACER Valuation Summary
- ACER's price/sales ratio is 9.4; this is 147.37% higher than that of the median Healthcare stock.
- Over the past 188 months, ACER's price/sales ratio has gone NA NA.
- Over the past 188 months, ACER's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ACER.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACER | 2021-08-31 | 9.4 | 4.8 | -2.2 | -0.9 |
| ACER | 2021-08-30 | 9.1 | 4.7 | -2.1 | -0.8 |
| ACER | 2021-08-27 | 9.1 | 4.7 | -2.1 | -0.8 |
| ACER | 2021-08-26 | 9.2 | 4.7 | -2.2 | -0.8 |
| ACER | 2021-08-25 | 9.2 | 4.7 | -2.2 | -0.8 |
| ACER | 2021-08-24 | 9.2 | 4.7 | -2.2 | -0.8 |
ACER Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at -135.65%.
- The 4 year price growth rate now stands at -84.36%.
- The 4 year net cashflow from operations growth rate now stands at -93.43%.
The table below shows ACER's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 3.998133 | 0.915877 | -16.90639 |
| 2021-03-31 | 3.998133 | -8.952031 | -19.44992 |
| 2020-12-31 | 0 | -17.02742 | -22.88545 |
| 2020-09-30 | 0 | -17.13891 | -21.80405 |
| 2020-06-30 | 0 | -20.0669 | -21.12727 |
| 2020-03-31 | 0 | -24.82641 | -26.39797 |
ACER Price Target
For more insight on analysts targets of ACER, see our ACER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.83 (Hold) |
ACER Stock Price Chart Interactive Chart >
ACER Price/Volume Stats
| Current price | $2.46 | 52-week high | $5.39 |
| Prev. close | $2.47 | 52-week low | $2.28 |
| Day low | $2.46 | Volume | 49,900 |
| Day high | $2.56 | Avg. volume | 609,077 |
| 50-day MA | $2.52 | Dividend yield | N/A |
| 200-day MA | $2.91 | Market Cap | 35.20M |
Acer Therapeutics Inc. (ACER) Company Bio
Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest ACER News From Around the Web
Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Acer Therapeutics Inc. common stock – ACERNEW YORK, Sept. 06, 2021 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of Acer Therapeutics Inc. common stock (NASDAQ:ACER): SUMMARY NOTICE OF PENDENCY AND PROPOSED SECURITIES CLASS ACTION SETTLEMENT TO: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF ACER THERAPEUTICS I |
Penny Stocks to Buy Using Technical Analysis for September 2021If you've been meaning to invest in penny stocks and learn more about technical analysis, there's no better time than now. |
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceNEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021. |
Argininosuccinic Aciduria Market Inherited Growth Prospects by 2021-28| Horizon Therapeutics, Acer Therapeutics, Evox TherapeuticsArgininosuccinic aciduria is a rare genetic disorder characterized by deficiency or lack of the enzyme argininosuccinate lyase (ASL). This enzyme is one of six enzymes that play a role in the breakdown and removal of nitrogen from the body, a |
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate UpdateNEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2021 and provided an update on the Companys recent corporate developments. |
ACER Price Returns
| 1-mo | 1.65% |
| 3-mo | -11.83% |
| 6-mo | -29.31% |
| 1-year | -5.02% |
| 3-year | -92.03% |
| 5-year | -93.09% |
| YTD | -6.11% |
| 2020 | -34.66% |
| 2019 | -80.07% |
| 2018 | 45.27% |
| 2017 | 45.45% |
| 2016 | -66.79% |
Loading social stream, please wait...